Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium.
Antipsychotics
PP1M
PP3M
Risperidone microsphere
Treatment continuation
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
07 06 2022
07 06 2022
Historique:
received:
04
10
2021
accepted:
28
02
2022
entrez:
7
6
2022
pubmed:
8
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment discontinuation of patients on paliperidone palmitate and risperidone microsphere. Additionally, treatment discontinuation between patients with PP1M and PP3M was compared. The IQVIA Longitudinal Prescription databases were used. Risk factors of treatment discontinuation were identified by a multilevel survival regression using Cox proportional hazards model. Kaplan Meier analyses were performed by identified significant risk factors. Twenty-five thousand three hundred sixty-one patients (France: 9,720; Germany: 14,461; Belgium: 1,180) were included. Over a one-year follow-up period, a significant lower treatment discontinuation was observed for patients newly initiated on paliperidone palmitate (53.8%) than those on risperidone microspheres (85.4%). Additionally, a significantly lower treatment discontinuation was found for 'stable' PP3M patients (19.2%) than 'stable' PP1M patients (37.1%). Patients were more likely to discontinue when drugs were prescribed by GP only (HR = 1.68, p < 0.001 vs. psychiatrist only) or if they were female (HR = 1.07, p < 0.001), whereas discontinuation decreased with age (31-50 years: HR = 0.95, p = 0.006 and > 50 years: HR = 0.91, p < 0.001 vs. 18-30 years). This study demonstrates that patients stay significantly longer on treatment when initiated on paliperidone palmitate as compared to risperidone microspheres. It also indicated a higher treatment continuation of PP3M over PP1M. Treatment continuation is likely to be improved by empowering GPs with mental health knowledge and managing patients by a collaborative primary care-mental health model. Further research is needed to understand why females and younger patients have more treatment discontinuation.
Sections du résumé
BACKGROUND
Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment discontinuation of patients on paliperidone palmitate and risperidone microsphere. Additionally, treatment discontinuation between patients with PP1M and PP3M was compared.
METHODS
The IQVIA Longitudinal Prescription databases were used. Risk factors of treatment discontinuation were identified by a multilevel survival regression using Cox proportional hazards model. Kaplan Meier analyses were performed by identified significant risk factors.
RESULTS
Twenty-five thousand three hundred sixty-one patients (France: 9,720; Germany: 14,461; Belgium: 1,180) were included. Over a one-year follow-up period, a significant lower treatment discontinuation was observed for patients newly initiated on paliperidone palmitate (53.8%) than those on risperidone microspheres (85.4%). Additionally, a significantly lower treatment discontinuation was found for 'stable' PP3M patients (19.2%) than 'stable' PP1M patients (37.1%). Patients were more likely to discontinue when drugs were prescribed by GP only (HR = 1.68, p < 0.001 vs. psychiatrist only) or if they were female (HR = 1.07, p < 0.001), whereas discontinuation decreased with age (31-50 years: HR = 0.95, p = 0.006 and > 50 years: HR = 0.91, p < 0.001 vs. 18-30 years).
CONCLUSIONS
This study demonstrates that patients stay significantly longer on treatment when initiated on paliperidone palmitate as compared to risperidone microspheres. It also indicated a higher treatment continuation of PP3M over PP1M. Treatment continuation is likely to be improved by empowering GPs with mental health knowledge and managing patients by a collaborative primary care-mental health model. Further research is needed to understand why females and younger patients have more treatment discontinuation.
Identifiants
pubmed: 35672743
doi: 10.1186/s12888-022-03914-2
pii: 10.1186/s12888-022-03914-2
pmc: PMC9171957
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Risperidone
L6UH7ZF8HC
Paliperidone Palmitate
R8P8USM8FR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
382Informations de copyright
© 2022. The Author(s).
Références
J Clin Psychiatry. 2009 Feb;70(2):196-200
pubmed: 19026261
Psychiatry Res. 2016 Feb 28;236:71-74
pubmed: 26743338
Endocr Metab Immune Disord Drug Targets. 2018;18(4):379-387
pubmed: 29165095
BMC Psychiatry. 2018 May 29;18(1):155
pubmed: 29843676
Acta Psychiatr Scand. 2014 Jul;130(1):46-51
pubmed: 24117209
Int J Clin Pharmacol Ther. 2019 Jul;57(7):329-333
pubmed: 31094315
Patient Prefer Adherence. 2013 Apr 04;7:275-84
pubmed: 23589681
Int J Clin Pharmacol Ther. 2020 Jan;58(1):37-49
pubmed: 31670653
J Psychosoc Nurs Ment Health Serv. 2013 Mar;51(3):13-8
pubmed: 23547305
Cochrane Database Syst Rev. 2013 Nov 04;(11):CD009531
pubmed: 24190251
J Affect Disord. 2019 Mar 15;247:156-160
pubmed: 30665077
Eur Neuropsychopharmacol. 2019 Sep;29(9):1051-1060
pubmed: 31362852
Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
pubmed: 25061342
Psychogeriatrics. 2022 Jan;22(1):159-160
pubmed: 34729877
Encephale. 2013 Sep;39 Suppl 2:S79-82
pubmed: 24084426
Int J Clin Pharmacol Ther. 2019 Sep;57(9):437-444
pubmed: 31232279
Psychiatry Res. 2017 Jan;247:257-264
pubmed: 27936437
Schizophr Res. 2014 Jul;156(2-3):228-32
pubmed: 24842538
Schizophr Res. 2009 May;110(1-3):1-23
pubmed: 19328655
J Manag Care Spec Pharm. 2016 Nov;22(11):1349-1361
pubmed: 27783548
BMC Psychiatry. 2013 Dec 20;13:340
pubmed: 24359031
PLoS One. 2017 Jun 14;12(6):e0179049
pubmed: 28614404
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Schizophr Bull. 2018 Apr 6;44(3):603-619
pubmed: 29868849
Int Clin Psychopharmacol. 2014 Jul;29(4):229-34
pubmed: 24419004
J Clin Psychiatry. 2013 Oct;74(10):957-65
pubmed: 24229745
J Clin Psychiatry. 2006 Jul;67(7):1114-23
pubmed: 16889456
BMC Psychiatry. 2015 Aug 12;15:193
pubmed: 26263900
Curr Med Res Opin. 2010 Oct;26(10):2403-10
pubmed: 20812791
Indian J Psychiatry. 2019 Jan;61(Suppl 2):277-293
pubmed: 30745703
J Clin Psychopharmacol. 2015 Oct;35(5):591-5
pubmed: 26267419
J Clin Psychiatry. 2019 Feb 19;80(1):
pubmed: 30786179
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216
Can J Psychiatry. 2017 Sep;62(9):604-616
pubmed: 28703015
Int J Ment Health Syst. 2011 May 23;5(1):13
pubmed: 21600067
Int Clin Psychopharmacol. 2015 Sep;30(5):272-81
pubmed: 26049673
Psychiatr Q. 2019 Mar;90(1):173-184
pubmed: 30484001
NPJ Schizophr. 2020 May 1;6(1):12
pubmed: 32358572